StockData
Interpace Biosciences, Inc. logo

Interpace Biosciences, Inc. (IDXG) stock

IDXGOTCSurgical & Medical Instruments & ApparatusFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 16, 2026Score 10/30
$5.00−0.15 (-2.91%)

Close on Oct 19, 2026Market cap $138.57MP/E 5.6Yield –

Interpace Biosciences revenue

Revenue is the money a company takes in from selling its products and services, before any costs are deducted.

Interpace Biosciences's revenue for the twelve months ending Jun 30, 2026 was $36.14M, down 20.5% year over year. For fiscal 2025 it was $38.73M, down 17.5% from the year before. Over ten years it grew 15.2% a year on average. The highest annual figure on record is $157.29M in fiscal 2011.

Annual revenue

PeriodPeriod endValueChange
FY2025Dec 31, 2025$38.73M-17.5%
FY2024Dec 31, 2024$46.93M+17.2%
FY2023Dec 31, 2023$40.04M+25.7%
FY2022Dec 31, 2022$31.84M+288.4%
FY2021Dec 31, 2021$8.20M-74.7%
FY2020Dec 31, 2020$32.40M+33.8%
FY2019Dec 31, 2019$24.22M+10.6%
FY2018Dec 31, 2018$21.90M+37.7%
FY2017Dec 31, 2017$15.90M+21.5%
FY2016Dec 31, 2016$13.09M+38.7%
FY2015Dec 31, 2015$9.43M+539.9%
FY2014Dec 31, 2014$1.47M-99.0%
FY2013Dec 31, 2013$146.53M+15.5%
FY2012Dec 31, 2012$126.90M-19.3%
FY2011Dec 31, 2011$157.29M+16.9%
FY2010Dec 31, 2010$134.59M–

Quarterly revenue

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$9.13M-1.1%
Q1 FY2026Mar 31, 2026$9.03M-21.6%
Q4 FY2025Dec 31, 2025$9.22M-25.7%
Q3 FY2025Sep 30, 2025$8.76M-28.8%
Q2 FY2025Jun 30, 2025$9.23M-23.3%
Q1 FY2025Mar 31, 2025$11.52M+13.1%
Q4 FY2024Dec 31, 2024$12.41M+22.5%
Q3 FY2024Sep 30, 2024$12.30M+33.6%
Q2 FY2024Jun 30, 2024$12.04M+9.0%
Q1 FY2024Mar 31, 2024$10.18M+5.4%
Q4 FY2023Dec 31, 2023$10.13M-61.3%
Q3 FY2023Sep 30, 2023$9.20M+626.4%
Q2 FY2023Jun 30, 2023$11.05M+464.7%
Q1 FY2023Mar 31, 2023$9.66M+293.4%
Q4 FY2022Dec 31, 2022$26.16M+51.1%
Q3 FY2022Sep 30, 2022$1.27M-84.3%
Q2 FY2022Jun 30, 2022$1.96M-82.5%
Q1 FY2022Mar 31, 2022$2.45M-75.0%
Q4 FY2021Dec 31, 2021$17.31M+79.4%
Q3 FY2021Sep 30, 2021$8.06M-2.3%
Q2 FY2021Jun 30, 2021$11.16M+104.8%
Q1 FY2021Mar 31, 2021$9.83M+8.5%
Q4 FY2020Dec 31, 2020$9.65M+128.8%
Q3 FY2020Sep 30, 2020$8.25M+6.8%
Q2 FY2020Jun 30, 2020$5.45M-13.1%
Q1 FY2020Mar 31, 2020$9.06M+50.7%
Q4 FY2019Dec 31, 2019$4.22M-27.8%
Q3 FY2019Sep 30, 2019$7.73M+34.3%
Q2 FY2019Jun 30, 2019$6.27M+14.0%
Q1 FY2019Mar 31, 2019$6.01M+25.0%
Q4 FY2018Dec 31, 2018$5.83M+33.5%
Q3 FY2018Sep 30, 2018$5.75M+36.9%
Q2 FY2018Jun 30, 2018$5.50M+42.7%
Q1 FY2018Mar 31, 2018$4.81M+38.6%
Q4 FY2017Dec 31, 2017$4.37M+40.0%
Q3 FY2017Sep 30, 2017$4.20M+26.7%
Q2 FY2017Jun 30, 2017$3.86M–
Q1 FY2017Mar 31, 2017$3.47M–
Q4 FY2016Dec 31, 2016$3.12M–
Q3 FY2016Sep 30, 2016$3.32M–

More Interpace Biosciences figures

See a number that looks wrong?